Related resources
Search for item elsewhere
University researcher(s)
Academic department(s)
Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma.
Currie G, Fowler SJ, Wilson A, Sims E, Orr L, Lipworth B
Thorax. 2002;57( 10):865-8.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Use our list of Related resources to find this item elsewhere. Alternatively, request a copy from the Library's Document supply service.
Abstract
BACKGROUND: With the transition to hydrofluoroalkane-134a propellants in metered dose inhalers, it is important to consider the efficacy and safety profiles of formulations containing inhaled corticosteroids. We examined the airway and systemic effects of hydrofluoroalkane-134a fluticasone propionate (FLU-HFA) and beclomethasone dipropionate (BEC-HFA) at recommended labelled doses. METHODS: Twenty mild to moderate asthmatics were randomised in crossover fashion to receive 6 weeks of 500 micro g/day followed by 1000 micro g/day FLU-HFA and BEC-HFA. Measurements were made at baseline after placebo run in and washout, and after each randomised treatment. The primary airway outcome for benefit was the dose of methacholine provoking a fall in forced expiratory volume in 1 second (FEV(1)) of 20% or more (methacholine PD(20)) and for systemic adverse effects was overnight urinary cortisol/creatinine (OUCC). RESULTS: For mean responses, both doses of BEC-HFA and FLU-HFA produced significant improvements in PD(20) compared with baseline. The improvement was not significantly greater with 1000 micro g/day FLU-HFA versus BEC-HFA, a 1.69 fold difference (95% CI 0.94 to 3.04). Both doses of BEC-HFA but not FLU-HFA caused significant suppression of OUCC compared with baseline, with significantly (p<0.05) lower values at 1000 micro g/day for BEC-HFA versus FLU-HFA (1.97 fold difference (95% CI 1.28 to 3.02)). CONCLUSION: There was no difference in the airway and systemic effects in patients with mild to moderate asthma between FLU-HFA and BEC-HFA at a dose of 500 micro g/day. At 1000 micro g/day there was increased systemic bioactivity with BEC-HFA compared with FLU-HFA, without any gain in airway efficacy.
Keyword(s)
Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Forced Expiratory Flow Rates; Humans; Male; Research Support, Non-U.S. Gov't; administration & dosage: Androstadienes; administration & dosage: Anti-Asthmatic Agents; administration & dosage: Beclomethasone; administration & dosage: Bronchoconstrictor Agents; administration & dosage: Bronchodilator Agents; administration & dosage: Hydrocarbons, Fluorinated; diagnostic use: Methacholine Chloride; drug effects: Forced Expiratory Volume; drug therapy: Asthma; metabolism: Creatinine; urine: Hydrocortisone